Trial reportAmerican journal of nephrology2008
5-methyltetrahydrofolate administration is associated with prolonged survival and reduced inflammation in ESRD patients.
Trial report in American journal of nephrology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05807711 (Efficacy of L-methylfolate and Methylcobalamine in Treating Resistant Hypertension Associated With Elevated Serum Homocysteine in Hemodialysis Patients.), which is not on this map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of L-methylfolate and Methylcobalamine in Treating Resistant Hypertension Associated With Elevated Serum Homocysteine in Hemodialysis Patients.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Interventions for lowering plasma homocysteine levels in dialysis patients.The Cochrane database of systematic reviews · 2016Pooled it
- The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis.BMJ (Clinical research ed.) · 2012Pooled it
- Efficacy of L-methylfolate and methylcobalamin in treating resistant hypertension associated with elevated serum homocysteine in hemodialysis patients.BMC nephrology · 2026Trial
- Review
- The association of metabolic profile of folate with diabetic kidney disease: evidence from 2011-2020 cycles of the NHANES.Renal failure · 2024Article
- Review
- One-carbon metabolites, B vitamins and associations with systemic inflammation and angiogenesis biomarkers among colorectal cancer patients: results from the ColoCare Study.The British journal of nutrition · 2020Article
- Review
- Novel genes associated with folic acid-mediated metabolism in mouse: A bioinformatics study.PloS one · 2020Article
- Folic Acid and Vitamin B12 Administration in CKD, Why Not?Nutrients · 2019Review
- Folic Acid and Homocysteine in Chronic Kidney Disease and Cardiovascular Disease Progression: Which Comes First?Cardiorenal medicine · 2017Review
- Fifteen-Year Analysis of Deceased Kidney Donation: A Single Transplant Center Experience in a Region of Northern Italy.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
- The Hydrogen Sulfide-Vitamin B12-Folic Acid Axis: An Intriguing Issue in Chronic Kidney Disease. A Comment on Toohey JI: "Possible Involvement of Hydrosulfide in B12-Dependent Methyl Group Transfer". Molecules 2017, 22, 582, pii: E582.Molecules (Basel, Switzerland) · 2017Article
- Vitamin B-6, Independent of Homocysteine, Is a Significant Factor in Relation to Inflammatory Responses for Chronic Kidney Disease and Hemodialysis Patients.BioMed research international · 2017Article
- Article
- Review
- Homocysteine-Lowering Interventions in Chronic Kidney Disease.Journal of research in pharmacy practiceReview
- Functional Abnormalities and Thyroid Nodules in Patients with End-stage Renal Disease.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHemodialysis (HD) patients have a greatly increased risk of cardiovascular morbidity and mortality. For this reason, attempts are often made to normalize hyperhomocysteinemia. This randomized prospective study sought to determine which risk factors are predictors of mortality and whether high doses of folates or 5-methyltetrahydrofolate (5-MTHF) could improve hyperhomocysteinemia and survival in HD patients.
methods341 patients were divided into two groups: group A was treated with 50 mg i.v. 5-MTHF, and group B was treated with 5 mg/day oral folic acid. Both groups received i.v. vitamin B(6) and B(12). By dividing patients into C-reactive protein (CRP) quartiles, group A had the highest survival for CRP <12 mg/l, whereas no survival difference was found for group B. CRP was the only predictive risk factor for death (RR 1.17, range 1.04-1.30, p = 0.02). Dialysis age, hyperhomocysteinemia, methylenetetrahydrofolate reductase polymorphism, albumin, lipoprotein (a) and folate did not influence mortality risk. Survival in group A was higher than that in group B, namely 36.2 +/- 20.9 vs. 26.1 +/- 22.2 months (p = 0.003).
resultsOur results suggest that CRP, but not hyperhomocysteinemia, is the main risk factor for mortality in HD patients receiving vitamin supplements. Intravenous 5-MTHF seems to improve survival in HD patients independent from homocysteine lowering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.